The KIFAP3 Knockout A-549 Polyclonal Cells are a pooled population of A-549 cells subjected to CRISPR/Cas9-mediated disruption of the KIFAP3 gene, creating a loss-of-function model for studying kinesin-associated protein 3. This polyclonal format preserves the parental genetic background while introducing heterogeneous gene knockouts, making it suitable for population-level assays and phenotypic screens without the need for clonal expansion. Gene editing was achieved via targeted ribonucleoprotein delivery, generating a mixed genotype pool.
The A-549 cell line is a human lung adenocarcinoma alveolar basal epithelial model derived from a 58-year-old Caucasian male. It displays adherent epithelial morphology, expresses wild-type p53 and surfactant proteins, and retains type II pneumocyte characteristics. This line is widely used in respiratory disease research, drug metabolism and toxicology, and lung cancer studies. Notably, A-549 cells can assemble primary cilia under defined conditions, offering a relevant platform for investigating ciliary and transport biology in a cancer context.
KIFAP3 encodes KAP3, the non-motor accessory subunit of the kinesin-2 motor complex (KIF3A/KIF3B/KAP3). KAP3 functions as an adaptor mediating cargo binding and regulation of anterograde microtubule-based transport within primary cilia and axons. This intraflagellar transport (IFT) is critical for ciliogenesis and hedgehog signaling. KAP3 drives the movement of hedgehog components SMO and GLI transcription factors along the cilium, enabling pathway activation. Upstream, SHH ligand and transcription factors FOXJ1/RFX2 control KIFAP3 expression; downstream, KAP3-dependent transport influences GLI1/2, SUFU, and Wnt/??-catenin signaling via APC interactions.
In the A-549 lung adenocarcinoma background, KIFAP3 knockout facilitates dissection of ciliary hedgehog signaling in tumor biology. Aberrant hedgehog activation is associated with proliferation, stemness, and drug resistance in cancers. Disruption of KAP3-mediated IFT may impair ciliary assembly and attenuate hedgehog transduction, allowing researchers to examine consequences on cell growth, migration, and invasion. This model also enables investigation of ciliopathy-like phenotypes in an oncogenic setting and testing of hedgehog pathway inhibitors.
Representative assays include western blotting for KAP3, KIF3A, and GLI1; RT-qPCR for GLI1, PTCH1, and HHIP; and immunofluorescence for acetylated ??-tubulin/ARL13B to visualize primary cilia. Functional studies employ MTS proliferation, Transwell migration/invasion, and flow cytometry for cell cycle. Transcriptome profiling via RNA-seq and drug sensitivity assays with hedgehog antagonists like GANT61 or cyclopamine further extend the model’s utility. For technical inquiries, please contact Ascent Research.
